Measurement of Plasma and Intracellular Concentrations of Raltegravir

Completed · Not applicable

Conditions studied: HIV

In brief

The primary purpose of this study is to analyze and compare plasma and intracellular concentrations of Raltegravir (RAL) in blood plasma and in peripheral blood mononuclear cells, using high performance liquid chromatography (HPLC).

Key facts

Study ID

NCT01214486

Run by

University of Nebraska

People needed

12

Starts

2010-10-01

Expected to finish

2011-06-30

Last updated by the study team

2017-08-21

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be of age greater than or equal to 19 years
• Have documented HIV
• Be taking RAL for at least 7 days

You may not qualify if…

• Any acute intercurrent illness that might interfere with the interpretation of the study

Where it is running

• University of Nebraska Medical Center — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.